Investigational drug · Phase 2
IBI355
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Sjögren's Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "IBI355"
First trial start
2026
Oct 15, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI355", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sjögren's Disease
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI355" as an intervention, largest first.
- A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's DiseasePivotal-lookingNot yet recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07836660 · 198 participants (planned) · Start Oct 15, 2026 · Primary completion Nov 1, 2027
Drug: Part A - Placebo for IBI355; Part B -Telitacicept and 2 more · For: Sjögren's Disease
Sites: Hefei, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06110338 · 53 participants · Start Oct 30, 2023 · Primary completion Sep 20, 2024
Drug: placebo; IBI355 · For: Healthy Subjects
Sites: Beijing, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06416787 · 32 participants · Start May 20, 2024 · Primary completion Feb 26, 2025
Drug: placebo; IBI355 · For: Healthy
Sites: Beijing, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06484855 · 30 participants · Start Jul 14, 2024 · Primary completion Jun 21, 2025
Drug: IBI355; IBI355 placebo · For: Primary Sjögren's Syndrome
Sites: Hefei, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Sjögren's Disease
- TelitaciceptRC18, RC18-LPhase 38 trials
RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease
- DDY391Phase 23 trials
Novartis · Moderate to Severe Psoriatic Arthritis, Sjögren's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.